清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Eсulizumab in treatment of ANCA-associated vasculitis complicated with Covid-19. Clinical observations

2019年冠状病毒病(COVID-19) 血管炎 2019-20冠状病毒爆发 严重急性呼吸综合征冠状病毒2型(SARS-CoV-2) 医学 病毒学 皮肤病科 免疫学 病理 疾病 爆发 传染病(医学专业)
作者
Н. Ф. Фролова,Natalia Tomilina,O.N. Kotenko Kotenko,O.L. Podkorytova,R.T. Ishakov,S.S. Usatyuk,Z. Yu. Mutovina,G.V. Volgina,G.V. Malyshev,V.V. Parshin,М. А. Лысенко
出处
期刊:Нефрология и диализ [Russian Dialysis Society]
卷期号:22 (Special_Issue): 33-45 被引量:3
标识
DOI:10.28996/2618-9801-2020-special_issue-33-45
摘要

Vasculitis associated with the antineutrophilic cytoplasmic antibodies (ANCA) is an autoimmune systemic severe, often life-threatening, disease characterized by necrotizing inflammation of small vessels. In 75-90% of cases of ANCA-associated vasculitis (AAV), a rapidly progressive pauci-immune necrotizing crescentic glomerulonephritis develops. Despite current treatment with high-dose glucocorticoids and either cyclophosphamide or rituximab, patients have a nine-fold increased mortality risk during the first year of disease compared with healthy subjects. This high mortality is attributed mainly to infections and vasculitis activity. Recent data suggest that the activation of the complement system, and in particular the alternative complement pathway, plays a significant role in the pathogenesis of AAV. It has been suggested that neutrophils primed by infection or pro-inflammatory cytokines release properdin, which activates an alternative complement cascade with cleavage of C5 into C5a and C5b. Anaphylatoxin C5a binds to receptors on the surface of neutrophils, enhancing their priming and activation and thus contributing to the inflammation. The randomized clinical trial showed that the selective C5a-receptor inhibitor avakopan was effective in the treatment of AAV. However, avacopan is currently not available in the everyday clinical practice. On the other hand, reports showing successful usage of monoclonal antibody against C5 eculizumab in severe AAV had been published. Here we present four cases of AAV complicated by COVID-19, for which conventional therapy with cyсlophosphamide could not be applied due to the particularly high risk of serious infectious complications, and eculizumab was used off-label by decision of the medical council and special commission. Taking this decision, we took into account data demonstrating the role of complement activation and, in particular, C5a in the pathogenesis of acute lung disease, induced by pathogenic viruses. Moreover, the successful usage of eculizumab in severe COVID-19 was reported recently. Thus, we sought to apply an approach aimed simultaneously at the pathogenetic mechanisms of both AAV and viral lung damage.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
zjkzh完成签到 ,获得积分10
9秒前
13秒前
junzzz完成签到 ,获得积分10
21秒前
22秒前
见物思理完成签到 ,获得积分10
27秒前
如懿完成签到,获得积分10
27秒前
如意亦瑶完成签到,获得积分10
29秒前
30秒前
38秒前
拼搏幻柏完成签到,获得积分10
39秒前
YNILY完成签到 ,获得积分10
44秒前
46秒前
岳晓燕完成签到 ,获得积分10
49秒前
55秒前
59秒前
luoqin完成签到 ,获得积分10
1分钟前
1分钟前
怼怼完成签到 ,获得积分10
1分钟前
1分钟前
机智的妙芹完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
zxdzaz完成签到 ,获得积分10
1分钟前
成就小蜜蜂完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
夕阳下仰望完成签到 ,获得积分10
1分钟前
1分钟前
典雅涵瑶发布了新的文献求助10
1分钟前
稳重的秋天完成签到,获得积分10
1分钟前
1分钟前
留胡子的翠容完成签到,获得积分10
1分钟前
1分钟前
典雅涵瑶完成签到,获得积分10
1分钟前
1分钟前
ww完成签到,获得积分10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185496
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834498
捐赠科研通 7783092
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558949
邀请新用户注册赠送积分活动 2481346